PATENT COOPERATION TREATY

TRANSLATION From the INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing See form PCT/ISA/210 (day/month/year) Applicant's or agent's file reference FOR FURTHER ACTION See paragraph 2 below P329905PC-La Priority date (day/month/year) International application No. International filing date (day/month/year) 28.03.2004 29.03.2005 PCT/DE2005/000589 International Patent Classification (IPC) or both national classification and IPC A61K9/127 Applicant NOVOSOM AG This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Priority Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. III Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis. 1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement Certain documents cited Box No. VI Box No. VII Certain defects in the international application Box No. VIII Certain observations on the international application **FURTHER ACTION** If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCI/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Authorized officer Name and mailing address of the ISA/EP

Telephone No.

Facsimile No.

International application No.
PCT/DE2005/000589

Bo	x No. I Basis of this opinion
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
	This opinion has been established on the basis of a translation from the original language into the following language, which is the language of a translation furnished for the purposes of international search (under
	Rule 12.3 and 23.1(b)).
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
	a. type of material
	a sequence listing
	table(s) related to the sequence listing
	b. format of material
	in written format
	in computer readable form
	c. time of filing/furnishing
	contained in the international application as filed.
	filed together with the international application in computer readable form.
	furnished subsequently to this Authority for the purposes of search.
3.	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4.	Additional comments:
	·
	·

International application No.
PCT/DE2005/000589

No. V				ive step or industrial applicability;	
Statement					
Novelty (N)	Claims		•	YES
		Claims	1-45		NO
Inventive	step (IS)	Claims			YES
		Claims	1-45		NO
Industrial	l applicability (IA)	Claims	1-45		YES
		Claims			NO
	Statement Novelty (citations and expla	Statement Novelty (N) Claims Claims Inventive step (IS) Industrial applicability (IA) Claims Claims	Claims Industrial applicability (IA) Claims supporting such statement Claims 1-45 Claims 1-45 Industrial applicability (IA) Claims 1-45	Claims Claims Claims Industrial applicability (IA) Claims I - 4 5

2. Citations and explanations:

Reference is made to the following documents:

- D1: WO 03/070735 A (NOVOSOM AG; ESSLER, FRANK; PANZNER, STEFFEN; ENDERT, GEROLT) 28 August 2003 (2003-08-28)
- D2: WO 02/066012 A (NOVOSOM AG; PANZNER, STEFFEN; FANKHAENEL, STEFAN; ESSLER, FRANK; PANZN)
 29 August 2002 (2002-08-29)
- D3: BUDKER V ET AL: "PH-SENSITIVE, CATIONIC LIPOSOMES: A

 NEW SYNTHETIC VIRUS-LIKE VECTOR" BIO/TECHNOLOGY,

 NATURE PUBLISHING CO. NEW YORK, US vol. 14, June 1996

 (1996-06), pages 760-764, XP002937150 ISSN: 0733-222X

The present application describes amphoteric liposomal formulations suitable for the intracellular delivery of oligonucleotides.

1. Novelty

The present application fails to meet the requirements of PCT Article 33(1) because the subject matter of claims 1--45 are not novel (PCT Article 33(2)).

Documents **D1 and D2** both disclose (reference passages, see ISR) amphoteric liposomes, suitable for delivering oligonucleotides and DNA/RNA, and the production

International application No.
PCT/DE2005/000589

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

thereof. Furthermore, the aforementioned liposomes are made up of the same or at least very similar compositions as the liposomes of the present application.

Document ${\bf D3}$ describes cationic liposomes to be used as virus vectors and anticipates the novelty of claim 1 of the present application.

2. Inventive step

The present application fails to meet the requirements of PCT Article 33(1) because the subject matter of claims 1-45 does not involve an inventive step (PCT Article 33(3)).

Should the applicant be able to dispel the abovementioned objections to novelty, he should also
simultaneously correct the relevance of documents D1D3 with regard to inventive step and existing
objections.

Industrial applicability

Claims 1-45 of the present application are considered industrially applicable.

PATENT COOPERATION TREATY

TRANSLATION INTERNATIONAL SEARCHING AUTHORITY To: WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (PCT Rule 43bis.1) Date of mailing See form PCT/ISA/210 Applicant's or agent's file reference FOR FURTHER ACTION See paragraph 2 below P329905PC-La Priority date (day/month/year) International filing date (day/month/year) International application No. 28.03.2004 29.03.2005 PCT/DE2005/000589 International Patent Classification (IPC) or both national classification and IPC A61K9/127 Applicant NOVOSOM AG This opinion contains indications relating to the following items: Box No. I Basis of the opinion Box No. II Priority Non-establishment of opinion with regard to novelty, inventive step and industrial applicability Box No. III Box No. IV Lack of unity of invention Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial Box No. V applicability; citations and explanations supporting such statement Box No. VI Certain documents cited Certain defects in the international application Box No. VII Certain observations on the international application Box No. VIII FURTHER ACTION If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered. If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCI/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220. For further details, see notes to Form PCT/ISA/220. Authorized officer Name and mailing address of the ISA/EP

Telephone No

Facsimile No.

International application No.
PCT/DE2005/000589

Box	x No. I	Basis of this opinion					
1.	With filed,	regard to the language, this opinion has been established on the basis of the international application in the language in which it was unless otherwise indicated under this item.					
		This opinion has been established on the basis of a translation from the original language into the following language					
	-	, which is the language of a translation furnished for the purposes of international search (under Rule 12.3 and 23.1(b)).					
_	4110-1	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed					
2.	inver	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed attended to the basis of:					
	a.	type of material					
		a sequence listing					
		table(s) related to the sequence listing					
	b.	format of material					
		in written format					
		in computer readable form					
	c.	time of filing/furnishing					
		contained in the international application as filed.					
		filed together with the international application in computer readable form.					
		furnished subsequently to this Authority for the purposes of search.					
3.	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.						
4.	Λἀdi	itional comments:					
1							
1							

International application No.
PCT/DE2005/000589

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industria citations and explanations supporting such statement				
1.	Statement			
	Novelty (N)	Claims		YES
		Claims	1-45	NO
	Inventive step (IS)	Claims		YES
		Claims	1-45	NO
	Industrial applicability (IA)	Claims	1-45	YES
		Claims		NO
			• '	

2. Citations and explanations:

Reference is made to the following documents:

- D1: WO 03/070735 A (NOVOSOM AG; ESSLER, FRANK; PANZNER, STEFFEN; ENDERT, GEROLT) 28 August 2003 (2003-08-28)
- D2: WO 02/066012 A (NOVOSOM AG; PANZNER, STEFFEN; FANKHAENEL, STEFAN; ESSLER, FRANK; PANZN)
 29 August 2002 (2002-08-29)
- D3: BUDKER V ET AL: "PH-SENSITIVE, CATIONIC LIPOSOMES: A
 NEW SYNTHETIC VIRUS-LIKE VECTOR" BIO/TECHNOLOGY,
 NATURE PUBLISHING CO. NEW YORK, US vol. 14, June 1996
 (1996-06), pages 760-764, XP002937150 ISSN: 0733-222X

The present application describes amphoteric liposomal formulations suitable for the intracellular delivery of oligonucleotides.

1. Novelty

The present application fails to meet the requirements of PCT Article 33(1) because the subject matter of claims 1-45 are not novel (PCT Article 33(2)).

Documents **D1 and D2** both disclose (reference passages, see ISR) amphoteric liposomes, suitable for delivering oligonucleotides and DNA/RNA, and the production

International application No.
PCT/DE2005/000589

Box No. V Reasoned statement under Rule 43bis, 1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

thereof. Furthermore, the aforementioned liposomes are made up of the same or at least very similar compositions as the liposomes of the present application.

Document **D3** describes cationic liposomes to be used as virus vectors and anticipates the novelty of claim 1 of the present application.

Inventive step

The present application fails to meet the requirements of PCT Article 33(1) because the subject matter of claims 1-45 does not involve an inventive step (PCT Article 33(3)).

Should the applicant be able to dispel the abovementioned objections to novelty, he should also
simultaneously correct the relevance of documents D1D3 with regard to inventive step and existing
objections.

Industrial applicability

Claims 1-45 of the present application are considered industrially applicable.